CAR-T-19 cell therapy（Inno Immunization）

N/A

Report date: 2024/07/30 17:49:30

Base Information

Drug NameCAR-T-19 cell therapy（Inno Immunization）
Drug Alias NameAnti-CD19 chimeric antigen receptor T cell therapy（Inno Immunization）因诺卡替-19细胞注射液
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLeukemia, Lymphoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesShenzhen Inno Immunization Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenzhen Inno Immunization Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Lymphoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A